|
Trial
|
Tumor type
|
Treatment (s)
|
n
|
Frequency of Toxicity [n= (%)]
|
Median PFS (months)
|
|---|
| | | | |
HT ≥ grade 2
|
HFSR ≥ grade 2
|
HT < grade 2 vs. ≥ grade 2
|
Log-Rank P =
|
HFSR < grade 2 vs. ≥ grade 2
|
Log-Rank P =
|
|---|
|
APC-CRPC
|
mCRPC
|
Bevacizuamb + Thalidomide + Docetaxel
|
60
|
15 (25.0)
|
4 (6.7)
|
14.9 vs. 31.5
|
0.0009
|
N/A*
|
ND*
|
|
BAY-BEV
|
ST
|
Sorafenib + Bevacizumab
|
27
|
15 (55.6)
|
13 (48.1)
|
3.7 vs. 11.9
|
0.052
|
3.7 vs. 12.6
|
0.094
|
|
BAY-CRPC†
|
mCRPC
|
Sorafenib
|
46
|
9 (19.6)
|
7 (15.2)
|
3.7 vs. 1.8
|
0.067
|
2.0 vs. 3.1
|
0.29
|
|
BAY-NSCLC
|
NSCLC
|
Sorafenib
|
22
|
9 (40.9)
|
10 (45.5)
|
1.9 vs. 4.6
|
0.19
|
2.9 vs. 3.7
|
0.38
|
|
BAY-CRC
|
CRC
|
Sorafenib + Cetuximab
|
18
|
1 (5.6)
|
2 (11.1)
|
N/A*
|
ND*
|
4.7 vs. 8.7
|
0.0065
|
|
BAY-KS‡
|
KS
|
Sorafenib +/- Protease inhibitor
|
8
|
3 (37.5)
|
2 (25.0)
|
N/A*
|
ND*
|
N/A*
|
ND*
|
- *Not done (ND). Patients were not evaluated in this analysis due to low frequency of toxicity (i.e. APC-CRPC vs. HFSR and BAY-CRC vs. HT) or due to limited PFS data (KS).
- †3 Patients participating on this trial were also treated on APC-CRPC.
- ‡Two patients on BAY-KS trial received only sorafenib.
- C: Caucasian, AA: African-American, Others: Hispanic or Asians, mCRPC: metastatic castrate resistant prostate cancer, NSCLC: non-small cell lung cancer, CRC: colorectal cancer, KS: Kaposi's sarcoma, ST: solid tumors, HFSR: hand-foot skin reaction syndrome, NA: not applicable
